Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to -$404.1 million.

  • Kymera Therapeutics' Cash from Investing Activities fell 49.23% to -$235.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.1 million, marking a year-over-year increase of 87.20%. This contributed to the annual value of -$404.1 million for FY2024, which is 388.86% down from last year.
  • As of FY2024, Kymera Therapeutics' Cash from Investing Activities stood at -$404.1 million, which was down 388.86% from $139.9 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' Cash from Investing Activities registered a high of $139.9 million during FY2023, and its lowest value of -$422.6 million during FY2020.
  • Its 3-year average for Cash from Investing Activities is -$81.2 million, with a median of $20.5 million in 2022.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first plummeted by 2,463.31% in 2020, then skyrocketed by 581.74% in 2023.
  • Kymera Therapeutics' Cash from Investing Activities (Yearly) stood at -$422.6 million in 2020, then surged by 76.38% to -$99.8 million in 2021, then soared by 120.55% to $20.5 million in 2022, then skyrocketed by 581.74% to $139.9 million in 2023, then plummeted by 388.86% to -$404.1 million in 2024.